Visara Doses First Patient in Phase 2b Wet AMD Trial
Visara says its ASCEND trial is evaluating VIS-101 for sustained disease control in wet AMD.
Story updates
12:02:06 PM UTC
SquawkNews
Head-to-head trial designed to evaluate VIS-101’s potential for sustained disease control with extended treatment intervalsPhase 2a results showed approximately 50% of patients in the 6 mg treatment-naïve cohort remained retreatment-free six months after the last loading doseROCKVILLE, Md., Nov. 18…